Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

JIJack IllingworthCTChun Huat TehΜΚΜαρίνα Καρακάντζα

Discussion

Loading...

Member takes

Overview

Analysis shows ruxolitinib continuation improves composite outcomes in myelofibrosis following stem cell transplantation, highlighting GVHD challenges.

Key Points

  • Ruxolitinib continuation significantly improves GVHD-free relapse-free survival outcomes in myelofibrosis.
  • At one year, patients continuing ruxolitinib had GRFS of 42.9% compared to 15.4% for those stopping before conditioning.
  • Observational analysis assessed the impact of ruxolitinib and other variables on transplant outcomes in myelofibrosis.
  • Results suggest the need for optimized treatment protocols and donor selection to enhance transplant success.

Cite This Study

Illingworth et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df19https://doi.org/10.1182/blood-2025-4238
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation2025 · 6 citations
  2. 2Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial2025
  3. 3Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  4. 4An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025
  5. 5Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025